TEAD1 Antibody - #DF3141

Fig. 2 From: LINC00525 drives aggressive phenotypes in bladder cancer via YAP stabilization-mediated transcriptional activation LINC00525 interacts with YAP and facilitates YAP nuclear translocation. (A) Venn diagram showing overlapping target genes between LINC00525 and YAP. (B) WB (upper panels) and qPCR (lower panel) assays to examine the YAP protein and LINC00525 expression in the indicated cells. Left panel shows the expression levels of YAP and LINC00525 in T24 cells transfected with LINC00525 shRNA lentivirus or sh control. Right panel shows expression levels of YAP and LINC00525 in 87 cells transfected with empty vector and LINC00525 expression vector. The control/sh control is used as the control in the qPCR data. (C) WB (upper panels) and qPCR (lower panel) detection of YAP protein and LINC00525 levels in normal bladder lines (SV) and bladder cancer lines (EJ, 87, T24, 5637, 253). The SV is used as the control in the qPCR data. (D) Left: WB and qPCR assays to examine the YAP protein and LINC00525 expression in BLCA tissues (T) and normal bladder tissues (N), GAPDH protein served as control (upper panels). Right: Correlation curve of YAP and LINC00525 expression in BLCA and bladder tissues by quantification. The N1 is used as the control in the qPCR data. (E) Pie chart of LINC00525 subcellular localization analyzed by lncLocator (http://www.csbio.sjtu.edu.cn/bioinf/lncLocator/). (F) Immunoblotting for specific associations of YAP with LINC00525 from RNA pull-down assays (top). RIP assay was executed in T24/87 lysates using anti-YAP or anti-IgG, then the enrichment of LINC00525 was detected by qRT-PCR (bottom). (G) T24 cells expressing LINC00525 shRNA or overexpressing LINC00525 were immunostained with a YAP-specific antibody (red). DAPI (blue) was used to stain DNA. Scale bar: 20 μm. (H) LINC00525 facilities YAP nuclear accumulation as demonstrated by western blotwestern blot. Lamin B1 was used as the nucleus marker and GAPDH as the cytoplasm marker. (I) Western blot shows the total and phosphorylated protein of YAP and its target genes (CYR61, CTGF and ANKRD1) in T24 cells expressing LINC00525 shRNA or 87 cells expressing exogenous LINC00525. (J) Western blot shows the total and phosphorylated protein of YAP and its target genes (CYR61, CTGF and ANKRD1) in T24 cells expressing LINC00525 shRNA or 87 cells expressing exogenous LINC00525. (K). Western blot shows that treatment of the indicated T24 or 87 cells with GA-017 or Cytochalasin D could reverse the effects of LINC00525 knockdown/overexpression on YAP and its target genes. All values shown are mean ± SD of triplicate measurements and have been repeated 3 times with similar results (*p 

Figure 3. Immunoblotting bands (a) and statistical analysis (b) of MST1, LATS1, YAP1, TEAD1, and β-actin for: 1, GP; 2, LP; 3, DP. The relative abundance of target proteins at each stage was expressed as the ratio of the measured intensity of MST1, LATS1, YAP1, TEAD1 protein, and β-Actin protein (target protein/β-actin). **, the expression of the same protein was significantly different at different periods